Patient-Centered Prescription Opioid Tapering Methods
Annals of Internal Medicine · 2026-09 · 179 (9) · 1221-1231
DOI: 10.7326/annals-25-04784 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2026-09. Verfasst von Beth D Darnall und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, and Stanford Pain Relief Innovations Lab, Palo…. Hauptthemen laut MEDLINE: Analgesics, Opioid, Chronic Pain, Drug Tapering, Cognitive Behavioral Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Evidence is needed on tapering long-term prescription opioids in outpatient settings. OBJECTIVE: To determine and compare the effectiveness of 3 opioid tapering and pain control strategies (July 2018 to November 2023). DESIGN: Randomized controlled trial. (ClinicalTrials.gov: NCT03445988). SETTING: 11 U.S. sites. PARTICIPANTS: Adults with pain for at least 6 months receiving a morphine equivalent daily dose (MEDD) of 10 or higher for at least 3 months without moderate or severe opioid use disorder. INTERVENTION: Patient-centered opioid tapering with close monitoring and electronic supports was administered as taper only, taper plus cognitive behavioral therapy for chronic pain (pain-CBT), or taper plus a chronic pain self-management program (CPSMP). MEASUREMENTS: Taper success (primary outcome) was either an MEDD decrease of at least 50% with no increased pain or no MEDD increase with decreased pain intensity. RESULTS: A total of 562 participants were randomly assigned (191 taper only, 203 taper plus pain-CBT, 168 taper plus CPSMP). The taper success rate was 50.9% (95% CI, 42.9% to 58.9%) for taper only, 48.6% (CI, 41.0% to 56.2%) for taper plus pain-CBT, and 44.5% (CI, 36.0% to 53.3%) for taper plus CPSMP. Tapering with pain-CBT or CPSMP provided no benefit in taper success over taper only (taper plus pain-CBT vs. taper only, -2.4 percentage points [CI, -11.9 to 7.2 percentage points]; taper plus CPSMP vs. taper only, -5.2 percentage points [CI, -15.3 to 4.8 percentage points]). Study-related adverse event risk (including opioid withdrawal symptoms) was highest in the taper only group (126 of 191 [66%]) compared with taper plus pain-CBT (109 of 203 [54%]) and taper plus CPSMP (108 of 168 [64%]). LIMITATION: Challenges related to COVID-19 reduced the sample size and made treatment groups imbalanced; low behavioral treatment attendance and losses to follow-up could have limited effectiveness. CONCLUSION: Adding CBT or self-management to patient-centered opioid tapering did not improve taper success at 12 months, although CBT may reduce adverse effects (including opioid withdrawal symptoms). PRIMARY FUNDING SOURCE: Patient-Centered Outcomes Research Institute.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, and Stanford Pain Relief Innovations Lab, Palo Alto, California (B.D.D.).
- Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, California (L.P., P.F., W.B., H.P.-K., V.S., L.S.S., J.H.).
- Stanford Pain Management Center, Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, California (M.-C.K.).
- Department of Rheumatology, Stanford University School of Medicine, Palo Alto, California (K.L.).
- Department of Family, Community and Preventive Medicine, University of Arizona College of Medicine - Phoenix, and Veterans Affairs Phoenix Health Care System, Phoenix, Arizona (A.S.M.).
- Vi Palo Alto, Palo Alto, California (T.P.).
ORCID-Profile: Beth D Darnall, Luzmercy Perez, Pamela Flood, William Brose, Luana Colloca, Mark McGovern, Vafi Salmasi, Jiapeng Xu, Sean C Mackey
Zitieren
APA
Darnall, B. D., Perez, L., Kao, M. C., Lorig, K., Mardian, A. S., Flood, P., Pun, T., Hanson, E. R., Brose, W., Chen, C. A., Cheung, M., Colloca, L., De Bruyne, K., Edelson, N., Kim, E., McGovern, M., Moore, N., Nicholson, B. D., Porter, J., …, & Mackey, S. C. (2026). Patient-Centered Prescription Opioid Tapering Methods. Annals of Internal Medicine, 179(9), 1221-1231. https://doi.org/10.7326/annals-25-04784
Vancouver
Darnall BD, Perez L, Kao MC, Lorig K, Mardian AS, Flood P, et al. Patient-Centered Prescription Opioid Tapering Methods. Annals of Internal Medicine. 2026;179(9):1221-1231. doi:10.7326/annals-25-04784
BibTeX
@article{Darnall2026,
author = {Darnall, Beth D and Perez, Luzmercy and Kao, Ming-Chih and Lorig, Kate and Mardian, Aram S and Flood, Pamela and Pun, Ting and Hanson, Eric R and Brose, William and Chen, Chwen-Yuen A and Cheung, Matthias and Colloca, Luana and De Bruyne, Korina and Edelson, Naomi and Kim, Eileen and McGovern, Mark and Moore, Nathaniel and Nicholson, Bruce D and Porter, Joel and Poupore-King, Heather and Salmasi, Vafi and Stieg, Richard L and Sinjary, Lanja S and Xu, Jiapeng and Hong, Juliette and Tian, Lu and Mackey, Sean C},
title = {Patient-Centered Prescription Opioid Tapering Methods},
journal = {Annals of Internal Medicine},
year = {2026},
volume = {179},
number = {9},
pages = {1221--1231},
doi = {10.7326/annals-25-04784}
}
EUVIMED